Market Overview

Markets are rallying Thursday as the U.S.-Iran Memorandum of Understanding signed yesterday offsets a hawkish first FOMC meeting under new Chair Kevin Warsh, who held rates at 3.5-3.75% while raising the 2026 inflation outlook and leaving the door open for a rate hike. Oil prices are sliding on the peace framework, providing consumer relief, while Trump’s announcement that Apple will work with Intel on U.S.-made chips is electrifying the semiconductor complex. The tension between geopolitical optimism and a Fed that’s clearly done cutting creates a “risk-on with a ceiling” environment.

Claude’s Call

UP — The Iran deal de-risks the energy shock that’s been hanging over markets for months, and falling oil prices act as a tax cut for consumers; I expect the S&P 500 to close +0.5-0.8% today as the geopolitical relief outweighs Fed anxiety, though gains will be capped by the rate hike specter.

Top Movers

BFLY (+30.9%) — $7.64 → $6.20 (SELL — overextended) Thesis: Butterfly Network is ripping on momentum from its TD Cowen presentation and a broader medtech sympathy bid, but this is a sub-$1B market cap ultrasound company with no fundamental catalyst that justifies a 31% single-day move. RSI at 80.2 screams overbought — this is a classic presentation pump that historically fades within 3-5 sessions. The stock was at $5.54 five days ago and $4.10 a month ago; this is retail chasing a volatile small-cap. Levels: No clear resistance overhead given 52-week breakout. Support at $5.50 (prior presentation day close).

INTC (+7.2%) — $133.27 → $145.00 (+8.8% upside) Thesis: Trump announced Apple has agreed to work with Intel on U.S. chip design and manufacturing — this is a genuine catalyst that validates Intel’s foundry strategy and could represent billions in future revenue. The stock has been a turnaround story all year and this is the kind of marquee customer win that changes the narrative. Multiple analysts likely raising targets today. Levels: Exit near $145 (likely faces resistance at round number + prior swing highs). Support at $124 (pre-announcement level).

WDC (+7.3%) — $790.59 → $850.00 (+7.5% upside) Thesis: Western Digital (now trading as SanDisk post-split) is riding the memory supercycle driven by AI data center buildout. Morgan Stanley just raised its price target, the stock is up 49% in a week, and Apple’s admission that memory/storage costs are “surging” validates the pricing power thesis. However, RSI at 80.3 and a 49% weekly gain means this is dangerously extended — the move is real but chasing here requires a strong stomach. Levels: Exit at $850 (psychological resistance). Support at $530 (pre-breakout level, but that’s 33% below — the risk/reward for new entries is poor).

EAT (+7.4%) — $164.82 → $175.00 (+6.2% upside) Thesis: Brinker International (Chili’s parent) continues its remarkable restaurant turnaround story, catching a tailwind today from the Iran deal pushing gas prices below $4/gallon — cheaper gas = more dining out. RSI at 65.9 suggests room to run before overbought. The stock is benefiting from both company-specific execution and a macro tailwind for consumer discretionary. Levels: Exit at $175 (prior high area). Support at $153 (week’s low).

ICHR (+7.5%) — $98.45 → $110.00 (+11.7% upside) Thesis: Ichor Holdings is riding the semiconductor equipment spending wave, up 393% over the past year as AI capex flows through to equipment suppliers. The Intel-Apple news today further validates massive U.S. chip manufacturing buildout that requires Ichor’s fluid delivery and chemical delivery systems. Insiders have been selling (CEO dumped 13K+ shares), which is the yellow flag — but insiders sell for many reasons during 400% runs. Levels: Exit at $110 (round number resistance). Support at $91.50 (pre-week breakout level).

DYN (+7.4%) — $20.21 → $23.00 (+13.8% upside) Thesis: Dyne Therapeutics just submitted its BLA to the FDA for its Duchenne muscular dystrophy treatment AND completed enrollment for its DM1 trial — these are legitimate, de-risking regulatory milestones. Canaccord had a $17 target which the stock has now blown through; expect target upgrades. This is a real catalyst story, not sector sympathy. Levels: Exit at $23 (prior swing high territory). Support at $18.40 (pre-breakout level).

Headlines to Watch

  • Trump says Apple agreed to work with Intel on U.S. chip manufacturing — This is the biggest news of the day for semis; validates Intel’s foundry pivot and could trigger a wave of analyst upgrades across the chip equipment supply chain (ICHR, UCTT benefit directly).
  • U.S.-Iran MOU signed, oil prices sliding below pre-war levels — Gas below $4/gallon is a direct stimulus to consumer discretionary names; watch restaurant, retail, and travel stocks for follow-through.
  • Fed Chair Warsh holds rates, signals possible hike ahead — The new Fed is clearly more hawkish than Powell’s; growth stocks with elevated multiples face headwinds, and “Bond King” Gundlach comparing this to 1970s inflation is not a comforting analogy.
  • Apple to raise product prices citing surging memory/storage chip costs — Direct confirmation that the memory supercycle (WDC/SanDisk) has pricing power; this is bullish for memory names but potentially bearish for Apple’s unit volumes.
  • Nvidia CFO comments on entering $200B market — Kress’s comments about competing in a new market should worry AMD and Intel investors long-term, even as Intel celebrates today’s Apple news.
  • Kevin Warsh skips individual dot plot forecast — A break with tradition that signals the new Fed wants maximum flexibility; markets hate uncertainty, and this creates a persistent valuation headwind for rate-sensitive names.

Claude’s Top Picks

INTC (+7.2% today, +14.0% week) — $133.27 → $145.00 (+8.8% upside) Valuation: At ~20x forward earnings with a genuine foundry revenue catalyst now confirmed, Intel looks reasonably priced vs. TSMC at 25x and far cheaper than NVDA at 35x given the re-rating potential. Upside: Apple partnership validates the foundry model, likely triggers multiple analyst upgrades and could catalyze other U.S. OEMs to announce similar deals; narrative shift from “turnaround hope” to “turnaround reality.” Risk: Nvidia’s entry into adjacent markets (per CFO comments today) and execution risk on actually delivering Apple’s chips at competitive yields — Intel has disappointed on manufacturing timelines before.

DYN (+7.4% today, +12.6% week) — $20.21 → $23.00 (+13.8% upside) Valuation: Clinical-stage biotech so traditional metrics don’t apply, but the BLA submission and trial enrollment completion represent genuine de-risking that justifies a re-rate above Canaccord’s $17 target. Upside: Priority Review designation if granted would compress the timeline to commercialization; the DMD market is $5B+ TAM with limited competition, and a completed BLA is the biggest regulatory milestone short of approval. Risk: FDA could issue a Refuse to File letter or request additional data; biotech binary outcomes mean position sizing matters more than conviction.

EAT (+7.4% today, +3.8% week) — $164.82 → $175.00 (+6.2% upside) Valuation: Trading at ~18x forward P/E with 20%+ earnings growth — PEG under 1.0 makes this genuinely cheap vs. restaurant peers like CMG (down 38% this year) and PLAY (in turnaround mode). Upside: Falling gas prices are a direct tailwind to casual dining traffic; the company is executing on its turnaround and Wall Street coverage remains bullish with significant upside to consensus targets. Risk: Consumer spending deceleration if the Fed actually hikes; restaurant comps are tough to sustain at this growth rate and any traffic slowdown gets punished severely.

ICHR (+7.5% today, +17.2% week) — $98.45 → $110.00 (+11.7% upside) Valuation: After a 393% one-year return, the stock looks expensive on trailing metrics, but forward estimates are being revised sharply higher on AI capex; at ~22x forward earnings for a company growing revenue 40%+, the PEG is still reasonable. Upside: Intel-Apple deal means more U.S. fab construction which directly drives orders for Ichor’s fluid and gas delivery subsystems; this is a “picks and shovels” play on the domestic chip manufacturing boom. Risk: Insider selling at these levels is a clear caution flag; semiconductor equipment is deeply cyclical and any capex pullback would hit this name hard — the CEO selling 13K shares says he thinks risk/reward is getting balanced.

Avoid

BFLY (+30.9%, RSI 80.2) — A 31% move on a conference presentation with no new product launch, partnership, or earnings beat is pure speculative froth. The stock was $4.10 a month ago; this is a momentum trap that will give back at least half the gains within a week. No institutional buyer is chasing a $7.64 medtech stock up 31% on a webcast.

WDC (+7.3%, RSI 80.3, +49% week) — The thesis is real (memory supercycle, Morgan Stanley upgrade), but up 49% in a single week with RSI over 80 means the good news is fully priced. Chasing here offers terrible risk/reward — if you’re not already in, wait for a pullback to $650-700 before entering. A 49% weekly gain in a $310B market cap stock is exhaustion territory.

GOLF (+5.9%, RSI 77.0) — Acushnet is riding the golf participation boom, but analysts have been cutting targets ($99→$96) and calling the stock “unpopular.” At RSI 77 with recent skeptical Wall Street coverage, this looks like a sector sympathy move that fades. The consumer discretionary rotation could easily reverse if the Fed hike narrative takes hold.

WSB Sentiment Check

SPCX — WSB says: BEARISH (30% bullish) Claude says: PARTIALLY AGREE — This ticker is likely getting memed as a proxy for SPX/market shorts after the hawkish Fed; WSB bears are playing the “Fed will crash the market” card. They’re not wrong that Warsh is more hawkish than expected, but betting against equities the day after an Iran peace deal with oil crashing is poor timing. Wait for the geopolitical relief rally to exhaust before shorting.

MSFT — WSB says: BULLISH (80% bullish) Claude says: AGREE — Microsoft’s AI monetization through Copilot and Azure continues to justify premium multiples. With the Fed on hold (not hiking yet) and the company printing cash, this is one of the safest large-cap tech longs. The 80% bullish consensus is appropriate for once.

MU — WSB says: MIXED (55% bullish) Claude says: AGREE IT’S MIXED — Micron benefits from the same memory supercycle driving WDC’s insane run, but MU hasn’t moved as aggressively, creating a “catch-up” thesis. The Apple pricing comments today are directly bullish for MU’s DRAM margins. I’d lean bullish here — the mixed sentiment means positioning isn’t crowded.

NBIS — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — Nebius (the Yandex AI infrastructure spinoff) is a legitimate AI infrastructure play, but 80% bullish WSB consensus on a recently-listed company often marks short-term tops. The thesis is sound but entry timing matters; wait for a pullback if you’re not in.

META — WSB says: BULLISH (80% bullish) Claude says: AGREE — Meta’s AI investments are generating real revenue growth, Reels monetization continues improving, and the stock is reasonably valued at ~23x forward earnings for 20%+ growth. WSB is right to be bullish, and unlike most of their picks, this one has the fundamentals to back it up.

Earnings Scorecard

WLYB (John Wiley & Sons) — BEAT | Stock: +4.9% | Reported: Tuesday After Close Q4 FY2026 delivered record margins with “sharply higher cash flow” and AI revenue growth driving the beat. Management raised full-year growth guidance and announced the Emerald acquisition for strategic expansion. The +4.9% reaction looks appropriate-to-slightly-muted given record margins — this is a boring publisher that just proved its AI data licensing strategy works. Modest buy on any dip below $44.